Comparative efficacy of switching to natalizumab in active multiple sclerosis. - Wikidata - awgldk - TriplyDB

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

http://www.wikidata.org/entity/Q35469575

about

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations Observational data: Understanding the real MS world.Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany.Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?Treatment decisions in multiple sclerosis - insights from real-world observational studies.Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.Predictors of long-term disability accrual in relapse-onset multiple sclerosis.The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.The importance of collecting structured clinical information on multiple sclerosis.Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis.Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.Long-term registries: Answering tough questions with big data?["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy].

P2860

Q26752859-3A86BD5A-9EC8-45C5-B01A-8B9358631C82 Q30249781-252E6812-91B3-4D7B-8E00-7C2243A6D6F7 Q33764067-6D7C6C55-360E-4DF3-9852-DD64D0B763D1 Q36202727-1FF7F4F2-D41C-49F9-BF8D-5B755F1C1B13 Q36484448-2B874615-F05F-4D32-A231-60DAED5EDAB5 Q36789883-F70FD559-5C95-4220-A34F-0269D11078CE Q36826621-5B25F4A6-B260-4F7B-B63E-540656E3AAC6 Q37626336-AD7F981E-1826-424C-ACCE-BA8EA93CF1DD Q38777286-CA2F89CB-5FBD-430B-9D2D-A8D22F269ABC Q39022643-3B3020D0-F1C3-45FF-8EF9-46C03094BEEF Q39675286-ECB762EA-1CAB-4124-BD76-BF7165FA2CCC Q39685700-F81A06CF-B6F1-4CEF-A873-51E57C6586B1 Q39732691-304D319E-AF83-4E07-9D72-D79BB82C636E Q39795220-E35283D1-DCD3-4B70-8898-F6C8C0FCAC76 Q40710140-2F1F3B94-8047-4CBD-96BE-ADD65EC19098 Q42747344-7D4148BA-61E8-4398-B328-B4050D269064 Q48204088-B3E5DABE-C2D0-4B3E-B346-AF3FCAD77FD5 Q48224174-5D878089-ED7D-433E-9D9E-CA2888EEF327 Q48910491-E85E7C72-73F3-4B73-AB1B-98EA196FBB1D Q48967402-45BB8DCB-BC83-47F2-986B-9615054C377C Q49353031-08AD2F54-DE2A-4433-AF71-2633709F9ECB Q53288359-9716D2D1-2AEA-4302-976E-F0A82CC0A609

P2860

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

http://www.wikidata.org/entity/Q35469575

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

@ast

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

@en

type

label

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

@ast

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

@en

prefLabel

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

@ast

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

@en

P1433

Q35469575-EF9B5F52-4B32-46CE-BD8A-3C52405EDCEB

P1476

Q35469575-EB133F87-BCE9-4539-B79F-7EBFABF741AD

P2093

Q35469575-0122C5B6-9681-4D12-9D9A-5D592059E454

Q35469575-17B06656-F390-4C4C-A710-1817D8DE82E3

Q35469575-242B7ED0-E796-4FF5-9CE0-8BEE405288B2

Q35469575-3976E752-CF13-40A0-9147-2401FA4CFE2A

Q35469575-44D3EEE6-5529-427E-AE7D-41C88C44D888

Q35469575-4E3BD1A5-AC9C-4EC8-9DD3-8F31B10C9286

Q35469575-5C07D433-BCB0-4D1F-BE66-D9F42BB4C1CD

Q35469575-8214CD3A-877D-46B7-B412-6563C01DBBF3

Q35469575-93EA06E3-5E34-4C02-9688-26ECDDDF80D1

Q35469575-A575B1FB-7047-4DD5-9924-B5B710EDCA10

P2860

Q35469575-11C35C69-D0C4-4744-81B2-EA7B50E0F162

Q35469575-176DA3E9-FCCF-4C95-9497-9A7770C10ECE

Q35469575-184F1C6F-F4CC-487A-AF2C-25AFB8BE464A

Q35469575-18F4C563-3565-4EF6-A5D1-A66154447BA9

Q35469575-32DABB70-2AD0-4A1E-81B6-8BFA6591FBE3

Q35469575-4173C494-390C-45F4-BC4E-32359FC80A91

Q35469575-4A0898E0-CC51-4F5C-AA63-55C3BBB889FB

Q35469575-4B3D3A15-480A-4197-9B6F-BB5D1327E2D3

Q35469575-4C471D9D-AA47-4CF1-9F8A-C5CC10743C61

Q35469575-52C338FF-93CB-4505-9330-4BFF916C9A00

P304

Q35469575-70D61AD2-EA1E-420B-BEC4-D220BA738032

P31

Q35469575-E76974C9-6B4F-4C09-B967-F32761F8E807

P356

Q35469575-DE8E5004-6A74-43EA-A257-0EDFA81CA0E8

P433

Q35469575-ADA905F6-22CD-4A29-825A-4D392647C05E

P478

Q35469575-1FB7DECC-DC7B-4D45-846F-26D7B5123243

P50

Q35469575-203FC84A-BA92-42A6-9BC6-8CBFB0F89C3C

Q35469575-5C4018D1-7953-4577-8CE0-B52B855779C5

Q35469575-82DA7CE8-19B0-4A2C-8675-0AD689F561E9

Q35469575-9F6BB4B4-1913-487E-8F43-38F666199912

Q35469575-AE91EA93-3F26-4B51-807E-AB4BFBCDB435

Q35469575-FBAD8660-2F43-481A-8334-1CA8FE574E94

P577

Q35469575-A38395FC-92F9-4CD4-9994-3DF84FF9B87E

P5875

Q35469575-6A811FE6-26CC-40C6-AB48-66414E6D2ACE

P698

Q35469575-8C4479D4-DF70-46E4-BE76-37029955DD9A

P932

Q35469575-AEED6A54-D365-477A-9F81-90AD23AA43C1

P356

P1433

Annals of clinical and translational neurology

P1476

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

@en

P2093

Annie Zhang

http://www.w3.org/2001/XMLSchema#string

Celia Oreja-Guevara

http://www.w3.org/2001/XMLSchema#string

Fabio Pellegrini

http://www.w3.org/2001/XMLSchema#string

Francois Grand-Maison

http://www.w3.org/2001/XMLSchema#string

Freek Verheul

http://www.w3.org/2001/XMLSchema#string

Guillermo Izquierdo

http://www.w3.org/2001/XMLSchema#string

Jeannette Lechner-Scott

http://www.w3.org/2001/XMLSchema#string

Larisa Tsvetkova

http://www.w3.org/2001/XMLSchema#string

Michael Barnett

http://www.w3.org/2001/XMLSchema#string

Pierre Duquette

http://www.w3.org/2001/XMLSchema#string

P2860

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.

Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.

P304

373-387

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACN3.180

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Helmut Butzkueven

Alessandra Lugaresi

P577

2015-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273005510

http://www.w3.org/2001/XMLSchema#string

P698

25909083

http://www.w3.org/2001/XMLSchema#string

P932

4402083

http://www.w3.org/2001/XMLSchema#string